http://www.ncbi.nlm.nih.gov/pubmed/23676440
Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Treatment of patients withdual hepatitis C and B by peginterferon α and ribavirin reduced risk ofhepatocellular carcinoma and mortality. Gut. 2014;63(3):506-14.

Abstract

OBJECTIVE:

Whether peginterferon α and ribavirin combination therapy reduces risk of hepatocellular carcinoma (HCC) or improves survival in patients dual-infected with hepatitis C virus (HCV) and hepatitis B virus (HBV) is unknown. Since it is ethically impossible to conduct a randomised trial to learn the long-term efficacy, we rely upon the large database to explore the effectiveness of combination therapy among dual-infected patients.

DESIGN:

http://www.ncbi.nlm.nih.gov/pubmed/24316262
Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L,Brown RS Jr, Hézode C, Rizzetto M, Paraná R, De Meyer S, De Masi R, Luo D,Bertelsen K, Witek J. Telaprevir twice daily is noninferior to telaprevir every 8hours for patients with chronic hepatitis C. Gastroenterology. 2014Mar;146(3): 744-753.

Abstract

BACKGROUND & AIMS:

We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis.

METHODS:

http://www.ncbi.nlm.nih.gov/pubmed/24445570
Roberts HW, Utuama OA, Klevens M, Teshale E, Hughes E, Jiles R. Thecontribution of viral hepatitis to the burden of chronic liver disease in theUnited States. Am J Gastroenterol. 2014;109(3):387-93.

Abstract

OBJECTIVES:

Chronic liver disease (CLD) is increasingly recognized as a major public health problem. However, in the United States, there are few nationally representative data on the contribution of viral hepatitis as an etiology of CLD.

METHODS: